To maintain its position as the leading manufacturer of injectable drugs and freeze-dried powder drugs in Vietnam, in the context of fierce competition in product quality and price with domestic and foreign enterprises in the integration period, the company always focuses on investing in the field of research and development; cooperating well with universities and research institutes; applying science, technology and engineering to research new products; improving formulas and preparation techniques, improving the quality and treatment effectiveness of specific specialty drugs, and enhancing product competitiveness.
Injection production line at the pharmaceutical factory of Vinh Phuc Pharmaceutical Joint Stock Company - Vinphaco.
Since 2023, the company has cooperated with the Vietnam Lung Association to successfully conduct a clinical research project on the application of Vinsalpium, a drug produced by the company, in the treatment of chronic obstructive pulmonary disease (COPD), ensuring safety and effectiveness equivalent to the original imported drug from Europe, but at a lower cost.
In 2024, the company will invest in a new production line using BFS technology with injections in plastic packaging, aerosols, and eye drops.
Actively implementing digital transformation, the company is deploying international standard ERP business management software SAP S/4HANA, officially operating from the beginning of November 2024.
Continue to innovate production technology, improve the quality of human resources, research and produce many specialized drugs with high quality and treatment effectiveness, serving the medical examination and treatment for people in the country and for export.
By improving product quality and efficiency, the company's products have won bids, serving well the medical examination and treatment of central and local hospitals nationwide and exporting to markets in Central Asia, South Asia, Africa and ASEAN.
Currently, there are more than 160 pharmaceutical products belonging to many treatment groups of the company distributed to more than 10 thousand medical facilities nationwide and more than 20 countries around the world.
In the past 3 years, the company's production and business activities have encountered many difficulties because more than 90% of the company's pharmaceutical raw materials have to be imported, and the supply chain has been disrupted due to the impact of post-Covid-19, geopolitical conflicts in the world...
Competition in the market is increasingly fierce. The company's main products, injectable drugs, must be made through bidding, and only those who win the bidding can be supplied to hospitals. The winning bid price often decreases over time.
Faced with that situation, the company has implemented innovative solutions, innovated corporate governance, innovated production technology, attracted high-quality human resources, improved the capacity of staff, applied digital transformation in management, production and business activities.
Thereby improving product competitiveness, company competitiveness and operational efficiency, achieving positive results.
Representatives of Vinh Phuc Pharmaceutical Joint Stock Company - Vinphaco presented 200 million VND through the Provincial Fatherland Front Committee to support the people in the North affected by storm No. 3 (Yagi).
The company's total revenue in the first 9 months of 2024 reached VND 585 billion, up 9% over the same period. Of which, revenue from pharmaceutical production - the company's main business sector - reached VND 402 billion, accounting for nearly 70% of production and business revenue, up 15% over the same period, ensuring stable jobs for 700 employees and paying full tax obligations to the State with the amount of VND 64 billion.
Along with maintaining production development, the company actively participates in community activities. In the first 9 months of 2024, the company sponsored more than 1.35 billion VND, of which, it supported the Fund of the Provincial Fatherland Front Committee and the Provincial Red Cross Society with 375 million VND to support people affected by storm No. 3 (Yagi).
With solutions to develop quality products at good prices, the company's brand reputation continues to be enhanced. On September 24, 2024, the company was honored to receive the Emulation Flag from the Government for its outstanding achievements in 2023; and was awarded the title "Vietnamese Medicine Star 2024" by the Ministry of Health.
Article and photos: Xuan Hung
Source: https://baovinhphuc.com.vn/tin-tuc/Id/118199/Cong-ty-co-phan-Duoc-pham-Vinh-Phuc---Vinphaco-Vi-suc-khoe-cong-dong
Comment (0)